Nymox Pharmaceutical NX-1207 for BPH
July 14, 2004 by admin · Leave a Comment
On July 14, 2004 Nymox Pharmaceutical Corporation reported FDA approval for the NX-1207 clinical trial protocol for benign prostatic hyperplasia (BPH). In January 2004 the company had reported Phase I results which indicated that safety and tolerability data were sufficient for the company to move NX-1207 into Phase II testing. The recent FDA ruling has [...]